Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Unraveling mechanisms of immunotherapy resistance through biomarker profiling in triple-negative breast cancer

Descrizione del progetto

Approfondimenti sulla resistenza all’immunoterapia nel cancro al seno

Il carcinoma mammario triplo negativo (TNBC) rappresenta il tipo di tumore al seno più aggressivo e difficile da trattare. Sebbene le nuove immunoterapie, come gli anticorpi anti-PD1, abbiano migliorato i risultati per alcune pazienti, spesso causano gravi effetti collaterali legati al sistema immunitario e la resistenza rimane comune. Con il sostegno del programma di azioni Marie Skłodowska-Curie, il progetto Bio3XBRIT studierà come le cellule immunitarie rispondono all’immunoterapia nelle pazienti con TNBC. I ricercatori analizzeranno le popolazioni di cellule T e l’espressione genica del tumore a livello di singola cellula per identificare biomarcatori in grado di prevedere la risposta e la tossicità del trattamento. Le intuizioni del progetto potrebbero portare a strategie di immunoterapia più sicure ed efficaci per il cancro al seno.

Obiettivo

Breast cancer remains a major public health issue, being the leading cause of cancer deaths among women in France, with around 58,459 new cases and 12,146 deaths reported in 2018. There are three main types: hormone receptor (HR)-positive (75-80% of cases), HER2-positive (15% of cases), and triple-negative breast cancer (TNBC) (15-20% of cases).
Standard treatment involves surgery, radiotherapy, chemotherapy, hormone therapy for HR-positive cases, and targeted anti-HER2 therapy for HER2-positive cases. Recently, immunotherapies like pembrolizumab (an anti-PD1 antibody) have been approved for TNBC patients, in combination with chemotherapy. However, immune checkpoint inhibitors are associated with immune-related adverse events (irAEs) due to generalized lymphocyte activation, which can affect any tissue and even lead to death in severe cases.
There is an urgent need to better understand the anti-tumor immune response to reduce toxicity, improve immuno-oncology strategies for TNBC, and broaden their application to other breast cancer types. Additionally, treatment resistance is a significant challenge, with unknown reasons limiting the number of patients achieving complete response.
The proposed project aims to advance breast cancer immunotherapy by developing a comprehensive molecular approach to discover TNBC immunotherapy biomarkers of treatment resistance and irAE development, thank to the access to TNBC patient cohorts.
Molecular characteristics and clonotype dynamics of T cells (CD8+, CD4+ Tconvs, and Tregs) at the single-cell level during anti-PD1 treatment, will be correlated with tumor transcriptomic data and clinical data. Analysis of an existing cohort of 83 TNBC patients treated with pembrolizumab and neoadjuvant chemotherapy will uncover aspects of the anti-tumor T-cell response, T-cell specificity, and identify novel biomarkers of resistance and toxicity, as well as targets for therapeutic options.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2024-PF-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

INSTITUT CURIE
Contributo netto dell'UE
€ 226 420,56
Indirizzo
RUE D ULM 26
75231 Paris
Francia
Regione
Ile-de-France Ile-de-France Paris
Tipo di attività
Research Organisations
Collegamenti
Costo totale
Nessun dato